drugset / Trial / NCT02387125
Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1b, open label, multi-center study of CMB305 (sequentially administered LV305 \[a dendritic cell-targeting viral vector expressing the NY-ESO-1 gene\] and G305 \[NY-ESO-1 recombinant protein plus GLA-SE\]) in patients with melanoma, sarcoma, ovarian cancer, or non-small cell lung cancer that express NY-ESO-1.
Timeline
- Start
- 2015-02-28
- Primary completion
- 2019-03-29
- Completion
- 2019-03-29
Outcome
Outcome not reported
Stopped: “This study did not meet the efficacy objective”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | G100 | Small molecule | — | Other |
| Subject | G305 | Protein / enzyme biologic | — | — |
| Subject | LV305 | Unknown | — | — |
| Subject | metronomic CPA | Unknown | — | Oral |